检索结果-内蒙古大学图书馆

PHASE 1B DOSE-ESCALATION STUDY OF ZN-C3 (WEE1 INHIBITOR) WITH CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER: ZN-C3 PLUS GEMCITABINE ARM

引用

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 2022年 32卷 A242-A242页

作者： Thaker, Premal Pasic, Anes Richardson, Gary Vranjes, Zivko Prather, Stanislava Makris, Lukas Misir, Soamnauth Pultar, Philippe Voliotis, Dimitris Fu, Siqing Washington Univ Div Gynecol Oncol Sch Med St Louis MO USA Univ Sarajevo Dept Oncol Clin Ctr Sarajevo Bosnia & Herceg Cabrini Hosp Malvern Med Oncol Melbourne Australia Univ Clin Ctr Republ Srpska Ctr Canc Banja Luka Bosnia & Herceg Zentalis Pharmaceut Clin Operat New York NY USA Zentalis Pharmaceut Biostat & Stat Programming New York NY USA Zentalis Pharmaceut Clin Dev New York NY USA Univ Texas MD Anderson Canc Ctr Invest Canc Therapeut Houston TX USA

TP039/#152

关键词：

来源：评论

学校读者我要写书评

暂无评论

Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study

CJC OPEN

引用

CJC OPEN 2020年第5期2卷 344-353页

作者： Haddad, Haissam Bergeron, Sebastien Ignaszewski, Andrew Searles, Gregory Rochdi, Driss Dhage, Priyanka Bastien, Natacha Univ Saskatchewan Dept Med Saskatoon SK Canada Univ Cardiol & Pneumol Quebec Ctr Rech Inst Dept Med Quebec City PQ Canada Univ British Columbia Dept Med Vancouver BC Canada St Johns Hosp Dept Med St John NB Canada Novartis Pharmaceut Canada Inc Med Affairs Dorval PQ Canada Novartis Pharmaceut Pvt Ltd Biostat & Stat Programming Hyderabad India Novartis Pharmaceut Canada Inc Med Affairs Dorval PQ Canada

Background: To determine the effectiveness of sacubitril/valsartan 97/103 mg twice daily (b.i.d.) on tolerability, safety, and quality of life (QoL) in Canadian patients with heart failure with reduced ejection fraction in a real-life setting. Methods: In Prospective, Multicenter, Open Label, Post-Approval Study Aimed at Characterizing the Use of LCZ696 at 97 mg Sacubitril/103 mg Valsartan bid in Patients With HFrEF (PARASAIL), an open-label, prospective, phase IV, multicentre study, outpatients with heart failure with reduced ejection fraction and New York Heart Association functional class II-III were followed up for 12 months. The suggested starting dose of sacubitril/valsartan was 24/26 mg b.i.d. replacing angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, with an uptitration to 97/103 mg b.i.d. or as per clinical judgement. The primary endpoint was the proportion of patients achieving the target dose of sacubitril/valsartan 97/103 mg b.i.d. after 6 months of ***: For the 302 patients included, the mean age was 64.47 years, and a majority of patients (82.8%) belonged to New York Heart Association class II. Overall, 195 (64.6%) patients were on maximum dose of sacubitril/valsartan 97/103 mg b.i.d. after 6 months and 62.3% remained on this dose at month 12. Using patient global assessment, patients experienced an improvement in QoL. For Minnesota Living with Heart Failure Questionnaire scores, a significant decrease from the baseline was observed at weeks 4, 12, and 24 (P < 0.0001 for all), which indicated an improvement in QoL. The patient global assessment and Minnesota Living with Heart Failure Questionnaire results correlate with moderate but significant changes in Euro quality of life-5D visual analogue scale ***: Results of the PARASAIL study in a real-life setting have shown that most patients were on sacubitril/valsartan 97/103 mg b.i.d. and the treatment was well tolerated. The patient-reported outcomes s

关键词：

来源：评论

学校读者我要写书评

暂无评论

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial

引用

DIABETES OBESITY & METABOLISM 2021年第6期23卷 1221-1231页

作者： McCrimmon, Rory J. Al Sifri, Saud Emral, Rifat Mohan, Viswanathan Sauque-Reyna, Leobardo Trescoli, Carlos Lalic, Nebojsa Alvarez, Agustina Demil, Nacima Coudert, Mathieu Shaunik, Alka Bonnemaire, Mireille Rosenstock, Julio Univ Dundee Sch Med Div Syst Med Dundee Scotland Al Hada Mil Hosp At Taif Saudi Arabia Ankara Univ Dept Endocrinol & Metab Dis Fac Med Ankara Turkey Dr Mohans Diabet Special Ctr Chennai Tamil Nadu India Madras Diabet Res Fdn IDF Ctr Excellence Diabet Care Chennai Tamil Nadu India ICMR Ctr Adv Res Diabet Chennai Tamil Nadu India Inst Diabet Obesidad & Nutr SC Cuernavaca Morelos Mexico Hosp Univ La Ribera Alzira Spain Univ Belgrade Clin Ctr Serbia Fac Med Clin Endocrinol Diabet & Metab Dis Belgrade Serbia Sanofi Buenos Aires DF Argentina Sanofi Diabet Med Operat Dept Chilly Mazarin France Sanofi Biostat & Programming Dept Chilly Mazarin France Sanofi US Bridgewater NJ USA Sanofi Paris France Dallas Diabet Res Ctr Med City Dallas TX USA

Aim Premix insulin is commonly used in some regions of the world, despite the higher risk of hypoglycaemia and weight gain compared with basal insulin, based on the premise that it offers a simplified insulin regimen. iGlarLixi is a once-daily titratable fixed-ratio formulation that combines basal insulin glargine 100 units/mL (iGlar) and the GLP-1 RA, lixisenatide, which offers a single-injection option for treatment intensification, with improved HbA1c reductions, similar hypoglycaemia risk and more favourable bodyweight profiles over iGlar alone. This randomized controlled study directly compares, for the first time, treatment intensification with iGlarLixi versus premix insulin analogue biphasic insulin aspart 30 (BIAsp 30) in adults with T2D inadequately controlled on basal insulin in combination with one or two oral antihyperglycaemic drugs. Materials and Methods This was an open-label, active-controlled, comparative, parallel-group, multicentre, phase 3b study. In total, 887 adults with T2D uncontrolled on basal insulin were randomized to switch to either iGlarLixi once daily, or BIAsp 30 twice daily, for 26 weeks. Results Overall, 887 participants were enrolled (mean age 59.8 years, 50.2% female) from 89 centres in 17 countries. At baseline, 65.6% had a duration of T2D of 10 years or longer, and the mean HbA1c at baseline was 8.6%. Conclusions The study directly compared the efficacy and safety of iGlarLixi versus BIAsp 30 in people with T2D uncontrolled on basal insulin and one or more oral antihyperglycaemic agents. These results provide robust clinical data that may inform clinicians in their therapeutic management of people with T2D uncontrolled on basal insulin requiring additional therapy.

关键词： basal insulin GLP‐ 1 analogue glycaemic control insulin therapy randomized trial type 2 diabetes

来源：评论

学校读者我要写书评

暂无评论

Correlation between patient engagement with a digital medicine system and clinical symptom improvement

引用

EUROPEAN NEUROPSYCHOPHARMACOLOGY 2021年 53卷 S374-S374页

作者： Cochran, J. Fang, H. Le Gallo, C. Peters-Strickland, T. Lindenmayer, J. P. Fowler, J. C. Otsuka Pharmaceut Dev & Commercializat Inc Data Sci Med & Real World Data Analyt Princeton NJ USA Otsuka Pharmaceut Dev & Commercializat Inc Biostat Princeton NJ USA Otsuka Pharmaceut Dev & Commercializat Inc Clin Programming Princeton NJ USA Otsuka Pharmaceut Dev & Commercializat Inc Global Clin Dev Princeton NJ USA NYU Grossman Sch Med Dept Psychiat New York NY USA

P.0508

关键词：

来源：评论

学校读者我要写书评

暂无评论

A phase 2, open-label, single-arm, prospective, multi-center study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer

引用

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 2023年第SUPPL_4期33卷 A249-A250页

作者： Dockery, Lauren Priebe, Anna Duska, Linda Green, Angela Mathews, Cara Musa, Fernanda O'Malley, David Puechl, Allison Ding, Li Schmid, Anita Navarro, Willis Slomovitz, Brian Moore, Kathleen Oklahoma Univ Hlth Stephenson Canc Ctr Gynecol Oncol Oklahoma City OK USA Texas Oncol Tyler TX USA Univ Virginia Charlottesville VA USA Mem Sloan Kettering Canc Ctr New York NY USA Women & Infants Hosp Rhode Isl Providence RI USA Swedish Canc Inst Seattle WA USA Ohio State Comprehens Canc Ctr Dept Obstet & Gynecol Columbus OH USA Atrium Hlth Gynecol Canc Levine Canc Inst Charlotte NC USA Aadi Biosci Biostat Programming & Data Management Pacific Palisades CA USA Aadi Biosci Clin Sci Pacific Palisades CA USA Aadi Biosci Clin Dev & Pharmacovigilance Pacific Palisades CA USA Mt Sinai Med Ctr Gynecol Oncol Miami Beach FL USA

TP009

关键词：

来源：评论

学校读者我要写书评

暂无评论

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

引用

BLOOD 2019年 134卷 1897-1897页

作者： Rachedi, Fatiha Koiwai, Kimiko Gaudel-Dedieu, Nadia Sebastien, Bernard Thai, Hoai-Thu El-Cheikh, Raouf Brillac, Claire Fau, Jean Baptiste Nguyen, Laurent Liu, Li Campana, Frank van de Velde, Helgi Veyrat-Follet, Christine Semiond, Dorothee Sanofi Translat Med & Early Dev Paris France Sanofi Biostat & Programming Bridgewater NJ USA Sanofi Oncol Cambridge MA USA

1897

关键词：

来源：评论

学校读者我要写书评

暂无评论

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab

引用

JOURNAL OF CLINICAL LIPIDOLOGY 2019年第3期13卷 443-454页

作者： Bruckert, Eric Kereiakes, Dean J. Koren, Michael J. Louie, Michael J. Letierce, Alexia Miller, Kathryn Cannon, Christopher P. Grp Hosp Pitie Salpetriere Serv Endocrinol Metab & Prevent Malad Cardiovasc Paris France Christ Hosp Lindner Res Ctr Heart & Vasc Ctr Cincinnati OH 45219 USA Jacksonville Ctr Clin Res Jacksonville FL USA Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA Sanofi Biostat & Programming Chilly Mazarin France Regeneron Pharmaceut Inc Biostat & Data Management 777 Old Saw Mill River Rd Tarrytown NY 10591 USA Harvard Clin Res Inst Prevent Cardiol Sect Boston MA USA

BACKGROUND: Patients with prior cardiovascular events are at very high risk of recurrent events and may benefit from low-density lipoprotein cholesterol (LDL-C) lowering beyond that achieved with maximally tolerated statins. OBJECTIVE: To assess potential differences between the efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab, in patients with vs without prior myocardial infarction (MI)/ischemic stroke. METHODS: Data (n = 4880) were pooled from nine ODYSSEY phase 3 trials of alirocumab 75/150 mg or 150 mg every 2 weeks, mostly on background statins other lipid-lowering therapies. Analyses were performed according to statin status, alirocumab dose, and control (placebo or ezetimibe). RESULTS: Baseline LDL-C, non high-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and apolipoprotein B levels were lower and lipoprotein(a) higher in patients with than without prior MI/ischemic stroke. LDL-C levels were reduced from baseline to week 24 in patients with (51.1%-62.9%) and without (43.6%-58.3%) prior MI/ischemic stroke, with no significant interaction between prior MI/ischemic stroke status and LDL-C lowering efficacy of alirocumab vs controls. Alirocumab significantly reduced other lipid/lipoproteins (including lipoprotein[a]) similarly in patients with/without MI/ischemic stroke. Week 24 LDL-C goal attainment rates for subgroups with/without prior MI/ischemic stroke on background statins were 74.1%-84.8% and 63.7%-74.7%, respectively. The safety profile of alirocumab was generally similar regardless of prior MI/ischemic stroke status. CONCLUSIONS: Alirocumab significantly reduced LDL-C and other atherogenic lipids/lipoproteins in patients with prior MI/ischemic stroke, and the majority of this very high cardiovascular risk population achieved LDL-C goals;efficacy and safety results were similar in patients without prior MI/ischemic stroke. (C) 2019 Published by Elsevier Inc. on behalf of National Lipid

关键词： Alirocumab Myocardial infarction Ischemic stroke PCSK9 Cardiovascular risk LDL-C

来源：评论

学校读者我要写书评

暂无评论

Ketolysis drives CD8+T cell effector function through effects on histone acetylation

引用

IMMUNITY 2023年第9期56卷 2021-+页

作者： Luda, Katarzyna M. Longo, Joseph Kitchen-Goosen, Susan M. Duimstra, Lauren R. Ma, Eric H. Watson, McLane J. Oswald, Brandon M. Fu, Zhen Madaj, Zachary Kupai, Ariana Dickson, Bradley M. DeCamp, Lisa M. Dahabieh, Michael S. Compton, Shelby E. Teis, Robert Kaymak, Irem Lau, Kin H. Kelly, Daniel P. Puchalska, Patrycja Williams, Kelsey S. Krawczyk, Connie M. Levesque, Dominique Boisvert, Francois-Michel Sheldon, Ryan D. Rothbart, Scott B. Crawford, Peter A. Jones, Russell G. Van Andel Inst Dept Metab & Nutr Programming Grand Rapids MI 49503 USA Univ Copenhagen Novo Nord Fdn Ctr Basic Metab Res Blegdamsvej 3B DK-2200 Copenhagen Denmark Van Andel Inst Bioinformat & Biostat Core Grand Rapids MI 49503 USA Van Andel Inst Dept Epigenet Grand Rapids MI 49503 USA Univ Penn Perelman Sch Med Cardiovasc Inst Philadelphia PA 19104 USA Univ Penn Perelman Sch Med Dept Med Philadelphia PA 19104 USA Univ Minnesota Dept Med Div Mol Med Minneapolis MN 55455 USA Univ Sherbrooke Dept Anat & Cell Biol Sherbrooke PQ J1E 4K8 Canada Van Andel Inst Mass Spectrometry Core Grand Rapids MI 49503 USA Univ Minnesota Dept Biochem Mol Biol & Biophys Minneapolis MN 55455 USA

Environmental nutrient availability influences T cell metabolism, impacting T cell function and shaping immune outcomes. Here, we identified ketone bodies (KBs)-including j3-hydroxybutyrate (j3OHB) and acetoacetate (AcAc)-as essential fuels supporting CD8+ T cell metabolism and effector function. j3OHB directly increased CD8+ T effector (Teff) cell cytokine production and cytolytic activity, and KB oxidation (ketolysis) was required for Teff cell responses to bacterial infection and tumor challenge. CD8+ Teff cells preferentially used KBs over glucose to fuel the tricarboxylic acid (TCA) cycle in vitro and in vivo. KBs directly boosted the respiratory capacity and TCA cycle-dependent metabolic pathways that fuel CD8+ T cell function. Mechanistically, j3OHB was a major substrate for acetyl-CoA production in CD8+ T cells and regulated effector responses through effects on histone acetylation. Together, our results identify cell-intrinsic ketolysis as a metabolic and epigenetic driver of optimal CD8+ T cell effector responses.

关键词： CD8+ T cells ketone bodies ketolysis metabolism TCA cycle effector function cancer immunology epigenetics acetyl-CoA

来源：评论

学校读者我要写书评

暂无评论

Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials

引用

BIOMETRICAL JOURNAL 2018年第3期60卷 516-536页

作者： Sun, Yanqing Qi, Li Yang, Guangren Gilbert, Peter B. Univ North Carolina Charlotte Dept Math & Stat Charlotte NC 28223 USA Sanofi Biostat & Programming Bridgewater MA 08807 USA Jinan Univ Sch Econ Dept Stat Guangzhou Guangdong Peoples R China Univ Washington Dept Biostat Seattle WA 98109 USA Fred Hutchinson Canc Res Ctr Seattle WA 98109 USA

This article develops hypothesis testing procedures for the stratified mark-specific proportional hazards model with missing covariates where the baseline functions may vary with strata. The mark-specific proportional hazards model has been studied to evaluate mark-specific relative risks where the mark is the genetic distance of an infecting HIV sequence to an HIV sequence represented inside the vaccine. This research is motivated by analyzing the RV144 phase 3 HIV vaccine efficacy trial, to understand associations of immune response biomarkers on the mark-specific hazard of HIV infection, where the biomarkers are sampled via a two-phase sampling nested case-control design. We test whether the mark-specific relative risks are unity and how they change with the mark. The developed procedures enable assessment of whether risk of HIV infection with HIV variants close or far from the vaccine sequence are modified by immune responses induced by the HIV vaccine;this question is interesting because vaccine protection occurs through immune responses directed at specific HIV sequences. The test statistics are constructed based on augmented inverse probability weighted complete-case estimators. The asymptotic properties and finite-sample performances of the testing procedures are investigated, demonstrating double-robustness and effectiveness of the predictive auxiliaries to recover efficiency. The finite-sample performance of the proposed tests are examined through a comprehensive simulation study. The methods are applied to the RV144 trial.

关键词： augmented inverse probability weighting auxiliary variables competing risks failure time data hypothesis testing semiparametric model two-phase sampling

来源：评论

学校读者我要写书评

暂无评论

Comparing Two Tests for Two Rates

引用

AMERICAN STATISTICIAN 2017年第3期71卷 275-281页

作者： Fan, Chunpeng Wang, Lin Wei, Lynn Sanofi US Inc Dept Biostat & Programming Bridgewater NJ 08807 USA

This article rigorously proves superiority of the proportion chi(2) test to the logistic regression Wald test in terms of power when comparing two rates, despite their asymptotic equivalence under the null hypothesis ... 详细信息

关键词： Logistic regression Parabola Proportion chi(2) test

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：